JP2021517119A5 - - Google Patents
Info
- Publication number
- JP2021517119A5 JP2021517119A5 JP2020546331A JP2020546331A JP2021517119A5 JP 2021517119 A5 JP2021517119 A5 JP 2021517119A5 JP 2020546331 A JP2020546331 A JP 2020546331A JP 2020546331 A JP2020546331 A JP 2020546331A JP 2021517119 A5 JP2021517119 A5 JP 2021517119A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- adenovirus
- combination
- inhibitor
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024186627A JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000210 | 2018-03-05 | ||
| EP18000210.7 | 2018-03-05 | ||
| PCT/EP2019/000067 WO2019170283A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024186627A Division JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517119A JP2021517119A (ja) | 2021-07-15 |
| JP2021517119A5 true JP2021517119A5 (cg-RX-API-DMAC7.html) | 2022-03-14 |
Family
ID=61569019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546331A Pending JP2021517119A (ja) | 2018-03-05 | 2019-03-05 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
| JP2024186627A Pending JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024186627A Pending JP2025013934A (ja) | 2018-03-05 | 2024-10-23 | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210038661A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3762004B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021517119A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210031852A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112533620B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019232768B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092907A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3762004T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965632T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3762004T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE064471T2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007873VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019170283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021044061A1 (en) * | 2019-09-05 | 2021-03-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| PL219321B1 (pl) * | 2002-10-15 | 2015-04-30 | Per Sonne Holm | Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny |
| WO2005052143A2 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| US9271988B2 (en) * | 2011-07-01 | 2016-03-01 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| RU2670762C2 (ru) * | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
-
2019
- 2019-03-05 SG SG11202007873VA patent/SG11202007873VA/en unknown
- 2019-03-05 DK DK19710999.4T patent/DK3762004T3/da active
- 2019-03-05 US US16/978,048 patent/US20210038661A1/en active Pending
- 2019-03-05 KR KR1020207025771A patent/KR20210031852A/ko not_active Ceased
- 2019-03-05 JP JP2020546331A patent/JP2021517119A/ja active Pending
- 2019-03-05 CN CN201980016785.2A patent/CN112533620B/zh active Active
- 2019-03-05 EP EP19710999.4A patent/EP3762004B1/en active Active
- 2019-03-05 KR KR1020267017074A patent/KR20260089640A/ko active Pending
- 2019-03-05 WO PCT/EP2019/000067 patent/WO2019170283A1/en not_active Ceased
- 2019-03-05 HU HUE19710999A patent/HUE064471T2/hu unknown
- 2019-03-05 CA CA3092907A patent/CA3092907A1/en active Pending
- 2019-03-05 ES ES19710999T patent/ES2965632T3/es active Active
- 2019-03-05 AU AU2019232768A patent/AU2019232768B2/en active Active
- 2019-03-05 FI FIEP19710999.4T patent/FI3762004T3/fi active
-
2024
- 2024-10-23 JP JP2024186627A patent/JP2025013934A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | The roles of EZH2 in cancer and its inhibitors | |
| Liontos et al. | Systemic therapy in cervical cancer: 30 years in review | |
| Gong et al. | Regulation of NANOG in cancer cells | |
| Guo et al. | Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1 | |
| Li et al. | Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy | |
| Feng et al. | A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients | |
| Er et al. | Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC) | |
| Yan et al. | LncRNA CCAT2 promoted osteosarcoma cell proliferation and invasion | |
| Pei et al. | miR-122-5p inhibits tumor cell proliferation and induces apoptosis by targeting MYC in gastric cancer cells | |
| Li et al. | Impact of Taurine on the proliferation and apoptosis of human cervical carcinoma cells and its mechanism | |
| Li et al. | p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma | |
| Thillai et al. | Molecularly targeted therapy for advanced hepatocellular carcinoma-a drug development crisis? | |
| Hou et al. | miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1 | |
| Chang et al. | Amiodarone promotes cancer cell death through elevated truncated SRSF3 and downregulation of miR-224 | |
| CN110545820A (zh) | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 | |
| Wu et al. | IFIT3: a crucial mediator in innate immunity and tumor progression with therapeutic implications | |
| FI3762004T3 (fi) | Kasvainten hoitaminen onkolyyttisen adenoviruksen ja CDK4/6-inhibiittorin yhdistelmällä | |
| Shen et al. | Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo | |
| JP2024125139A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Anticancer effects of myricetin derivatives in non‐small cell lung cancer in vitro and in vivo | |
| Wang et al. | Tambulin targets histone deacetylase 1 inhibiting cell growth and inducing apoptosis in human lung squamous cell carcinoma | |
| Alameddine et al. | From sprouting angiogenesis to erythrocytes generation by cancer stem cells: evolving concepts in tumor microcirculation | |
| Hashimoto et al. | The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment | |
| Wang et al. | TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells | |
| Nakhjavani et al. | Human lung carcinoma reaction against metabolic serum deficiency stress |